Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation
Status:
Withdrawn
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Allogeneic stem cell transplantation (SCT) remains a powerful therapeutic modality for
patients with acute myeloid leukemia (AML).The superior clinical outcomes of allogeneic human
SCT versus chemotherapy alone as post-remission treatment could be related to the
graft-versus-leukemia (GVL) effects of recovered donor T cells. Our previous study
investigated both the association of MRD status with transplant outcomes in haplo-SCT and
matched sibling donor transplantation(MSDT)， and also possible differences in the transplant
outcomes of patients with positive pre-MRD (as determined by MFC) who underwent haplo-SCT
versus MSDT. It provided new evidence that unmanipulated haplo-SCT is superior to matched
sibling donor transplantation in eradicating pre-transplantation MRD, indicating that
unmanipulated haploidentical allografts have stronger GVL effects.As to the AML patients in
standard-risk, who have a positive MRD before MSDT, whether these patients should be given
any relapse prevention is the question to be answered in this study. Interferon α-2b exerts a
relatively strong immunomodulatory effect. It can kill AL cells by regulating T-cell and/or
natural killer cell functions.Consequently, interferon α-2b may have potential value for
high-risk AL patients after transplantation. The study hypothesis: Using interferon α-2b
following hematopoietic stem cell transplantation in patients with standard-risk AML can
further reduce relapse rate and improve leukemia-free survival.